PodcastIntel
Sign in Get Started Free
HCPLive
HCPLive

Who Responds Best to First-Line Sarcoidosis Treatment?

Oct 7, 2026 · 0:06:39
Listen to Episode
✨ AI Summary
  • Analysis of PREDMETH trial examined predictors of response to prednisone or methotrexate.
  • Methotrexate was previously found noninferior to prednisone for pulmonary sarcoidosis.
  • Lower baseline forced vital capacity may predict treatment response in sarcoidosis.

Guests on This Episode

VK
Vivienne Kahlmann
1 podcast appearance

More from HCPLive

HCPLive
Subcutaneous Furosemide Bioequivalent to IV, Bioavailable Across Multiple Injection Sites
Oct 12, 2026 · 0:03:18
HCPLive
Targeting Senescent Cells in Actinic Keratosis With RLS-1496
Oct 12, 2026 · 0:04:25
HCPLive
Atopic Dermatitis Biologic Selection, With Raj Chovatiya, MD, PhD
Oct 12, 2026 · 0:03:33
HCPLive
Tovinontrine 50 mg Improves cGMP With Minimal Effect on NT-proBNP in HFpEF
Oct 12, 2026 · 0:06:00
View all episodes →

Get AI Summaries for Every New Episode

Subscribe to HCPLive and get AI summaries, guest tracking, and email digests delivered automatically.

Sign Up Free →